Biogen Amevive Marketing Focus Will Be Duration Of Antipsoriatic Response

Biogen will distinguish Amevive in the psoriasis market by emphasizing the biologic's duration of response following FDA approval Jan. 30

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet